Literature DB >> 24449236

Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.

Dae-Won Lee1, Hyun Chang, Yu-Jung Kim, Kwhan-Mien Kim, Hee-Jin Lee, Jong-Seok Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24449236     DOI： 10.1200/JCO.2012.48.1960

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.

Authors:  Cheng-Keng Chuang; Hsin Chia Angela Lin; Han-Yu Tasi; Kun-Han Lee; Yuting Kao; Fukai Leo Chuang; Ying-Hsu Chang; Po-Hung Lin; Chung-Yi Liu; See-Tong Pang
Journal:  Int Urol Nephrol       Date:  2017-05-25       Impact factor: 2.370

2.  Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.

Authors:  Fang Gao; Chengsuo Huang; Yiping Zhang; Ruirui Sun; Yujie Zhang; Huijun Wang; Shu Zhang
Journal:  Cancer Biol Ther       Date:  2016-03-30       Impact factor: 4.742

3.  Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/- Mice Is Superior to Everolimus Alone.

Authors:  Jian Yang; Paulina A Samsel; Kalin Narov; Ashley Jones; Daniel Gallacher; John Gallacher; Julian R Sampson; Ming Hong Shen
Journal:  Neoplasia       Date:  2017-01-13       Impact factor: 5.715
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.